Cite
HARVARD Citation
Berdunov, V. et al. (2023). Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer. European journal of surgical oncology. 49 (5), pp. e236-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Berdunov, V. et al. (2023). Combined cost-utility analysis of the 21-gene assay to guide chemotherapy in HR+/HER2- breast cancer. European journal of surgical oncology. 49 (5), pp. e236-. [Online].